Most tumour suppressor genes (TSGs) have been found through linkage studies in cancer predisposed families where the mutations have a high penetrance, for example, the breast cancer genes BRCA1 and BRCA2. Loss of heterozygosity (LOH) analyses of sporadic breast tumours indicate that there are many other putative TSGs yet to be identified. One such locus is proximal to BRCA1 on human chromosome 17q21. In an attempt to isolate this putative TSG, we have assessed a portion of the orthologous region on mouse chromosome 11 for its tumorigenic potential using segmental haploidy in combination with a p53 mutation. Two populations of animals were studied, with the deleted region being either on the same (cis) or on the homologous chromosome (trans) to a targeted mutant p53 allele. The deficiency elevated the tumour susceptibility of p53 heterozygous mice and modified the tumour spectrum, but only when the deficiency was in trans with the p53 mutation. Even though the genotype of these mice is identical, allelic phasing affects both the tumour spectrum and progression. Oncogene (2003Oncogene ( ) 22, 3288-3296. doi:10.1038 Keywords: p53; tumorigenicity; chromosome 11 deletion; loss of heterozygosity; mouse cancer model
Introduction
There are, as yet, an unquantified number of tumour suppressor genes (TSGs) in the mammalian genome, many or most of which are unknown at present. In addition, data from quantitative trait analysis in the mouse support the notion that there are many other TSGs to find, may be hundreds (Balmain, 2002a) . A proportion of TSGs have been localized and subsequently isolated through classical linkage studies of cancer in a familial setting. Examples of such genes include the genes for neurofibromatosis NF1 and NF2 (Viskochil et al., 1990; MacCollin et al., 1993) and the hereditary breast cancer genes BRCA1 and BRCA2 Miki et al., 1994; Tavtigian et al., 1996; Wooster et al., 1995) . The finding of the causative genes in inherited cancer predisposition syndromes has been of great importance to cancer genetics, but of less consequence to cancer prevention as these genes may account for only 1-2% of the overall cancer incidence (Ponder, 2001) . With respect to breast cancer, there is evidence to suggest that there are other familial breast cancer genes to discover, as BRCA1 and BRCA2 account for only 15-20% of familial cases (Anglian Breast Cancer Study Group, 2000) .
Apart from human linkage studies, there are other methods to find TSGs in the human genome, such as the use of loss of heterozygosity (LOH) studies from tumour samples and cancer cell lines, a so-called deletion mapping approach (Balmain, 2002b) . In this strategy, polymorphic microsatellite markers are used to find commonly deleted regions (CDRs) across the genome for a certain cancer, and then inactivating mutations in the other copy of the gene from the region are looked for. This mapping approach has been used in breast cancer, and has identified several CDRs. In a recent meta-analysis for breast cancer, 26 such CDRs were located on 16 chromosomes (Osborne and Hamshere, 2000) . One CDR is found on chromosome 17q21 proximal to BRCA1. However, somatic inactivation of BRCA1 in breast and ovarian cancer occurs rarely (Merajver et al., 1995; Staff et al., 2000) . This would indicate that there may be one or more TSGs in, or close to, this region. Even though there are many CDRs in the genome, it is very hard to find the causative TSG (Balmain, 2002b) , possibly because a TSG may not be inactivated by mutation but may be silenced by methylation or other types of epigenetic changes.
Owing to the large conserved linkage groups between the human and mouse genomes, it may be possible to identify TSGs using the mouse as a model system. The mouse genome is very amenable to germline modification in a variety of ways (reviewed in Bradley et al., 1998) . One method is to use Cre-loxP-mediated chromosome engineering to create deletions across large portions of the genome (up to 5 Mb) (Ramirez-Solis et al., 1995), thus removing one copy of a putative TSG and rendering that cell hemizygous. Subsequent to our initial chromosome engineering strategies, we have constructed many defined deletions on mouse chromosome 11 using a variety of approaches Zheng et al., 1999a, b; Su et al., 2000) . These large deletions (or deficiencies: Df) tend to be homozygous lethal . Thus, if the region contains a putative TSG, it is not possible to assess tumorigenicity by generating homozygous mice. However, it is possible to analyse heterozygous mice in many cases. Previously, we have examined mice with segmental haploidy of a region termed Df(11)1, proximal to Brca1. This is an B750 kb deletion (Figure 1) , extending from the gastrin gene to Hsd17b1 previously termed sporadic breast cancer locus I (SBCI) (Ramirez-Solis et al., 1995) .
Df(11)1 was constructed as a part of a balanced deletion/duplication strategy. Initially, the duplication mice (Dp(11)1) were studied as they showed corneal hyperplasia in a dose-dependent manner . We also assessed Df11(1)/+mice for their tumour susceptibility, but found that they were not more tumour prone than wild-type mice in an 18-month study (unpublished observations). To accelerate tumorigenesis, we established Df11(1)/+mice, which also carried a p53 mutation. Two populations of animals were studied, with the deleted region being either on the same (cis) or on the homologous chromosome (trans) to the targeted mutant p53 allele (Donehower et al., 1992) . Here we show that Df(11)1 elevated the tumorigenesis of p53 heterozygous mice and modified the tumour spectrum, but only when Df(11)1 was in trans with the p53 mutation. Thus, allelic phasing can affect both the tumour spectrum and progression even though the genotype of these mice is identical.
Results

Generation of OCH and OTH mice
In order to accelerate tumorigenesis, mice carrying a p53 targeted mutation were crossed with Df(11)1/+mice. The Df(11)1 region is located B30 Mb proximal to p53 (Figure 1 ; http://www.ensembl.org/Mus_musculus). Two different populations of compound heterozygotes were generated using the mating strategy shown in Figure 2 . Initially, mice that were heterozygous for each locus were used to generate a compound heterozygote with the targeting events in trans, an obligate trans heterozygote (OTH). OTH mice were backcrossed to C57BL/6-Tyr c-Brd mice, which produced individuals with the p53 targeted allele and Df(11)1 on the same chromosome. These mice were obligate cis heterozygotes (OCH), and occurred at a frequency of 10.1%, as expected, given that p53 and Df(11)1 were known to be B20 cM apart.
OTH and OCH mice have different survival curves compared to p53+/À mice Animals that were either OTH or OCH were monitored for the occurrence of spontaneous tumours up to 120 weeks of age. By this time, all the animals in the test populations had died ( Figure 3) . As all the animals in the study were p53+/À, this genotype was used to control for the role of Df(11)1. Kaplan-Meier survival curves were plotted for each genotype and compared. We found a significant difference in the survival of OTH and p53+/À mice by log-rank analysis (P ¼ 0.0022). There was tentative evidence for a difference between the OTH and OCH mice (P ¼ 0.033), and no difference between the OCH and p53+/À mice (P ¼ 0.440). Thus, the deficiency accelerates tumorigenesis in OTH mice, but not in OCH mice.
Tumour studies
Of the 116 animals in the study (61 OTH and 55 OCH), 109 were necropsied and, of those, 104 (58 OTH mice and 46 OCH mice) were subject to a full histopathological analysis in order to determine the tissue of origin of the tumour. Overall, 72 mice (69.2%) had tumours with a similar proportion being observed in both OTH (41/ 58; 70.7%) and OCH mice (31/46; 67.4%). This frequency is slightly higher than that observed in previous studies of p53+/À mice (Harvey et al., 1993; Donehower et al., 1995; Venkatachalam et al., 1998) . The results of the histopathological analysis on the OTH and OCH mice are summarized in Table 1 , along with previously published data for p53+/À mice (Donehower et al., 1995) to give a context for the OTH and OCH data. Examples of haematoxylin and eosin staining of some tumour types observed are shown in Figure 4 .
It has been observed previously that p53+/À mice develop more sarcomas than lymphomas (Donehower et al., 1992) . The results in Table 1 show that the predominant tumour types seen in OTH mice are lymphomas, whereas those in OCH mice are sarcomas. With the exception of carcinomas appearing in the OTH mice over 500 days old, there is no bias for sarcomas being diagnosed after lymphomas for either OTH or OCH mice (data not shown). Overall, the OCH mice show a spectrum much like p53+/À mice in terms of the proportions of lymphomas, sarcomas, carcinomas, and other tumour types (w 2 test, P ¼ 0.1299). However, the data also show that the OTH mice have a different tumour spectrum to p53+/À mice (w 2 test, P ¼ 0.0007). This spectrum is more like that seen for p53À/À mice, although they are still significantly different (w 2 test, P ¼ 0.0012). There is also evidence for a different tumour spectrum between the OCH and OTH mice (w 2 test, P ¼ 0.068). These data are somewhat unexpected, given that OTH and OCH mice have the same genotype and, therefore, the only difference between them is in the phasing of their targeted alleles ( Figure 2 ).
LOH analysis
Previous studies have revealed accelerated tumorigenesis in mice that carry two tumour suppressor gene mutations on the same chromosome because a single genetic event (such as a chromosome loss) uncovers two recessive mutations simultaneously. Thus, one might expect the OCH mice to be more tumour-prone than the OTH mice. In order to examine the conflicting role of the deficiency in OCH and OTH mice, 55 tumours were typed for LOH. A typical Southern blot of a subset of the tumours is shown in Figure 5a . This shows that certain tumours do not exhibit any detectable LOH (tumour 210A); some show a degree of allelic imbalance (tumours 548A, 721A, and 721B), while others clearly show LOH (for example, tumour 313A). Overall, LOH of the deletion was observed in just 7% of the OTH tumours and in 38% of the OCH tumours (Figure 5b ). By contrast, loss of p53 by LOH was observed in 68% of OTH and in 50% of OCH tumours (Figure 5b ).
The majority of the tumours arising in the OTH mice (16/23; 70%) show loss of Df(11)1 and the wild-type p53 allele (Figure 5b ). This means that these tumours are p53 null and wild type for the deleted region; thus it appears that simple chromosome loss has occurred. In order to assess the mechanism of LOH (segmental loss or chromosome loss plus reduplication), a reduction to the homozygosity approach was used. The mice used in this study were of a mixed 129S5/C57BL/6-Tyr of this chromosome will be homozygous (and thus noninformative). Microsatellite markers on chromosome 11 that show a difference in allele size between the two strains were identified. Nine markers were used to score alleles in tumour DNA that showed a loss of wild-type p53, irrespective of the status of Df(11)1; this was compared with tail DNA from the same animal. A total of 19 tumours from the 14 OTH mice were analysed. The PCR results, as well as those from the Southern blots for p53, are shown in Figure 6 . As expected, the homozygosity of the mice was extensive. While most of the OTH mice are not informative for markers from the centromere to 56 Mb, 13 of the tumours from these mice exhibit clear loss of multiple markers from 69 Mb to the telomere. In six mice, informative markers are available proximally and five of the tumours from these mice exhibit allele loss extending over the entire chromosome. Just two tumours (558A and 85B) show retention of heterozygosity of several linked markers. Thus, most of the OTH tumours appear to have lost heterozygosity by a chromosome loss event.
However, the situation is different with the OCH tumours. Firstly, loss of the Df(11)1 and p53-null chromosome was not observed, which confirms the role of p53 deficiency in these tumours. The OCH tumours that exhibit loss of the wild-type p53 allele fall into two categories. For 10 tumours from seven mice, microsatellite analysis of informative markers reveals that there is loss of the entire wild-type chromosome; the tumours are thus homozygous for the Df(11)1 allele. For four tumours, segmental loss was observed, so that the tumour is p53 null but the tumours retain both the deleted and wild-type copies of the deficiency allele. In two cases, wild-type copies of both the p53 gene and the deficiency allele are retained; thus p53 is most likely mutated by some other mechanism in these tumours.
Discussion
Taken together, the survival curves and tumour spectra illustrate that the OCH and OTH mice have different phenotypes, even though their genotype is the same -it is the phasing of their allelles that accounts for the phenotypic differences. In many respects, the OCH mice appear to be very similar to p53+/À mice. The OTH mice, however, are more tumour prone than p53+/À mice and their tumour spectra appear to be more like that observed in p53À/À mice, having an increased proportion of lymphomas and carcinomas as well as fewer sarcomas than p53+/À mice. The phenotype of the OTH mice clearly illustrates that the Df(11)1 allele is modifying tumour initiation and/or progression in the mice, but this effect is not observed in OCH mice. Determining the precise role of the deficiency may be complicated by the fact that LOH of the deletion would result in the loss of around 30 gene products, one or more of which might affect normal cell growth (Figure 1 ). The OCH mice can simultaneously lose the wild-type p53 allele and the deficiency allele by a simple nondisjunction event (loss of chromosome A for OCH mice in Figure 5b) . Indeed, detailed analysis with microsatellite markers reveals that 62% of the tumours have lost heterozygosity of the entire chromosome; thus the tumours have a 750 kb homozygous deletion. Tumours with a homozygous deficiency fall into the typical spectrum and latency of tumours observed in p53+/À mice. Four tumours in the OCH mice exhibit segmental LOH. These tumours have lost the wild-type p53 allele but retain the wild-type deficiency region (p53À/À, Df(11)1/+).
The tumours that arise in the OTH mice exhibit a higher rate of p53 LOH than seen in p53+/À or OCH mice. This increased frequency of LOH is consistent with the increase in tumour susceptibility and the tumour spectrum, which is more like that observed in p53À/À mice. We believe that the increased tumour susceptibility reflects a different mechanism operating in the OTH mice. In these tumours, microsatellite analysis reveals extensive LOH across the entire chromosome, and this pattern of loss converts p53+/À into p53À/À cells. It was expected that the mice should resemble p53+/À mice. However, the tumour spectrum is much more like p53À/À mice, suggesting that a portion of the cells in these mice may actually be p53 null. These cells could arise during development if there is somatic selection against cells with a Df(11)1/+ genotype in certain lineages. Indeed there is evidence for such a selection, because Df(11)1/+ mice are not recovered at the expected frequency in crosses to wild-type mice. These concepts are shown schematically in Figure 7 .
While a high frequency of LOH of the Df(11)1 allele (to produce tumours with a homozygous deletion) is observed in the OCH mice, this is most likely selected by linkage to p53, while in the OTH mice only a single tumour was observed where segmental LOH had generated a p53-deficient tumour that also had a homozygous Df(11)1 allele (Figure 5b ). Consequently, this may indicate that p53 exerts a stronger effect in terms of its tumour suppressor functions than does any putative TSG within Df(11)1. However, the development of early-onset tumours in the OCH mice might reflect a balance between TSG loss and the consequences of loss of cell viability genes in the deficiency interval. This possibility can be tested by examining smaller deletions that might separate loss of the TSG from the critical viability gene(s).
One indication of the role of the deficiency can be seen in the survival curve (Figure 3) . Clearly, both the OCH and OTH mice begin to develop tumours before the p53+/À mice. For example at 45 weeks, 10% of the OCH and OTH mice have tumours compared with none of the p53+/À mice. Even though there is evidence for the clear role of the deficiency in enhancing tumorigenesis, there is little evidence from the analysis here that loss of the deficiency region is itself required for tumorigenesis. Therefore, the implication of this observation is that any allele that has a selective disadvantage, when heterozygous, can result in an over-representation of cells that have lost this allele by a typical nondisjunction/reduplication event. Should this allele be in trans with a tumour predisposing mutation, then this mutation will have a greater chance of becoming homozygous and causing tumorigenesis.
It is not unexpected that p53 has a greater role in tumorigenesis than the putative TSG within Df(11)1 given our previous studies with p53+/À and Df(11)1/+ mice. This may explain why such TSGs cannot be found through conventional human linkage studies; the a b c Figure 4 Histopathological sections of tumours: (a) osteosarcoma, (b) lymphoma in liver, and (c) squamous carcincoma of the bowel penetrance may be low. However, if they are very common in the population, these lower penetrance alleles may be very important to the general cancer incidence, and are thus of paramount importance to isolate.
Recently, the phenotype of BlmÀ/À mice was reported (Luo et al., 2000) . The Blm locus encodes a gene that is the homologue of Escherichia coli RecQ DNA helicase. Enhanced sister chromatid exchange is seen in BlmÀ/À ES cells, and a wide tumour spectrum was seen in BlmÀ/À mice, both phenotypes seen in human BLM patients. The BlmÀ/À genetic background would be good to assess Df(11)1 tumorigenicity as the background tumour susceptibility is low (Luo et al., 2000) and there would be an increase in the number of Df(11)1/Df(11)1 cells generated in Df(11)1/+ mice.
There are just a few published examples where TSG mutations have been combined on the same chromosome. One study examined the modification of intestinal tumorigenesis in APC D716 mice by the TSG Dpc4 (Smad4) (Takaku et al., 1998) . Both of these genes are located on mouse chromosome 18 (although they are on human chromosomes 5q21 and 18q21, respectively). Takaku et al. compared APC D716 heterozygotes to cis heterozygotes (equivalent to p53+/À and OCH in our study) as the trans heterozygotes were phenotypically similar to single APC D716 heterozygotes. They showed that tumours in the cis heterozygotes were both larger in size, and more overtly malignant than those in APC D716 heterozygotes (Takaku et al., 1998) . These data are in contrast to our study, where the OCH and p53+/À mice were phenotypically similar, while the OTH mice were different.
The Nf1 gene has also been examined in cis and trans with a p53 mutation, given that Nf1 is 10 Mb distal to p53 (Vogel et al., 1999) . The introduction of a null Nf1 allele in either a cis or a trans configuration with the targeted p53 allele accelerated tumorigenesis (Vogel et al., 1999) . However, in the cis configuration, the mice died quicker than the p53À/À mice. LOH at both loci was seen in 71% of the soft tissue sarcomas tested. In addition, the tumour spectrum changed with the introduction of a null Nf1 allele.
In summary, we have shown that a defined region on mouse chromosome 11 can be assessed for tumorigenicity through a segmental haploidy approach as evidenced by the increased frequency of tumours in the OTH and OCH mice compared with their p53+/À background. Furthermore, there are significant differences between the test populations, both in terms of survival, and also of tumour spectrum. Given the (Mb)  199A  226A  297B  309A  309B  548A  823A  297A  932A  932B  1046A  309C  533A  533B  226B increasing ability to manipulate chromosomes both on a large and a small scale, it will be likely that more complex rearrangements and/or deletions and/or knockouts will be constructed in the mouse to phenocopy human mutations.
Methods
Generation of mice
The two heterozygous strains used to generate the obligate trans (OTH) and obligate cis (OCH) mice were developed in our laboratory, and were of a mixed 129S5/C57BL/6-Tyr c-Brd background. Both have been described previously (p53 (Donehower et al., 1992) and Df(11)1 ).
Genotyping
All genotyping was performed on 5 mg of tail biopsied DNA by Southern blotting essentially as described previously , but with a different hybridization buffer (Church and Gilbert, 1984) and a modification in the washing procedure. Blots were usually washed twice, in 2 Â SET (0.3 m NaCl, 40 mm Tris-Cl, pH 7.8, 2 mm EDTA), 0.2% SDS for 15 min at 651C, and then in 0.2 Â SET, 0.1% SDS at 651C for 15 min. Sometimes a further wash in 0.1 Â SET, 0.1% SDS at 651C for a further 15 min was required. The p53 probe used was to exons 2-6 of p53, as described previously (Donehower et al., 1992) . The diagnostic probe used to detect for the novel junction product associated with Df(11)1 was a 1.7 kb SacISpeI fragment located B6.5 kb distal of Hsd17b1.
Assessment of tumour susceptibility
OCH and OTH mice were bred so that there were at least 50 mice in each cohort, intially 61 for the OTH mice and 59 for the OCH mice. Four OCH mice were removed from the study, as these died in the flood at Baylor College of Medicine on 9th June 2001, leaving 55 OCH mice. Mice were monitored weekly for morbidity, cachexia, or tumours up to 120 weeks of age. Animals that were moribund or that were developing overt tumours were killed and necropsied. Samples of fresh tumour were taken for further analysis from some of the mice, before they were placed in 10% neutral formalin-buffered saline for subsequent histopathological analysis. Haematoxylin and eosin-stained paraffin sections were examined to determine the tumour type. Dates of death and tumour appearance were recorded for each mouse in order to construct tumour-free survival curves.
Statistical analyses
Kaplan-Meier analyses were performed using Statview 5.0 software (SAS Institute Inc.). w 2 correlation analyses were performed on the tumour spectra by comparison of the major categories of tumours (lymphomas, carcinomas, sarcomas, other) across the four genotypes by their relative percentages.
LOH
Genomic DNA was prepared from small quantities of the tumour samples using conventional methods. Southern blots using 5 mg of DNA were performed as described above. In order to look at the relative levels of each allele in the tumour samples, a Southern blot was designed that could detect the p53 alleles as well as Df (11)1 in the same lane of a genomic digest. BamHI was chosen as this was the enzyme used for the p53 genotyping. Using the genomic sequence from BACs that map to Df(11)1, a probe was chosen from one BAC (RP23-113E2) that would give an B5.5 kb band on a BamHI digest. Both this probe and the p53 probe were colabelled with [a-32 P]dCTP prior to hybridization.
Microsatellite marker analysis
For each marker to be analysed, DNA from the two strain backgrounds used in this study were used as controls, namely 129S5 and C57BL/6-Tyr c-Brd
. DNA (50 ng) was amplified using PCR in a 20 ml reaction volume that comprised 50 mm KCl, 10 mm Tris-HCl (pH 9.0 at 251C), 0.1% Triton s X-100, 1.5 mm MgCl 2 , 1 U Taq polymerase (Promega), 0.2 mm of each dNTP (Pharmacia), and 200 nm of each D11Mit marker. Amplification was performed with an initial denaturation cycle of 941C for 3 min, 35 cycles of 941C for 30 s, 551C for 30 s, 721C for 1 min, and a final extension at 721C for 2 min. After PCR, the samples were electrophoresed on a 3% agarose gel in 1 Â TBE, and visualized by ethidium bromide staining under UV light. Products from tumours that were heterozygous were scored for their relative intensity compared to that observed in the blood control as either a loss of one allele or as an allelic imbalance.
